JAKAFI Drug Patent Profile

Which patents cover Jakafi, and what generic alternatives are available?

Jakafi is a drug marketed by Incyte Corp and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Jakafi

Jakafi was eligible for patent challenges on November 16, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2028. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JAKAFI

International Patents:	236
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	81
Patent Applications:	2,133
Drug Prices:	Drug price information for JAKAFI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JAKAFI
What excipients (inactive ingredients) are in JAKAFI?	JAKAFI excipients list
DailyMed Link:	JAKAFI at DailyMed

See drug prices for JAKAFI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JAKAFI

NDA:

202192

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JAKAFI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Heart, Lung, and Blood Institute (NHLBI)	PHASE2
Incyte Corporation	PHASE2
University of Pennsylvania	PHASE2

See all JAKAFI clinical trials

Pharmacology for JAKAFI

Drug Class	Janus Kinase Inhibitor Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Paragraph IV (Patent) Challenges for JAKAFI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JAKAFI	Tablets	ruxolitinib phosphate	5 mg, 10 mg, 15 mg, 20 mg, and 25 mg	202192	1	2015-12-17

US Patents and Regulatory Information for JAKAFI

JAKAFI is protected by eight US patents and six FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No					Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-004	Nov 16, 2011		RX	Yes	No					Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-005	Nov 16, 2011		RX	Yes	Yes					Y

International Patents for JAKAFI

When does loss-of-exclusivity occur for JAKAFI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Nicaragua

Norway

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Tunisia

Turkey

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JAKAFI around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2011252024	HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINE AND PYRROLO[2,3-b]PYRIMIDINE AS JANUS KINASE INHIBITORS
Spain	2373688
Spain	2575797
Ukraine	116187	ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ

Supplementary Protection Certificates for JAKAFI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	2013C/014	Belgium		PRODUCT NAME: RUXOLITINIB; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001 20120828
1966202	122013000015	Germany		PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
1966202	2013/004	Ireland		PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THREOF; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
1966202	C300574	Netherlands		PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823

JAKAFI Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Understanding the JAKAFI Patent Landscape

JAKAFI (ruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of myelofibrosis (MF), polycythemia vera (PV), and graft-versus-host disease (GvHD). The drug is developed by Incyte Corporation. Its patent portfolio is critical to its market exclusivity and future revenue streams.

Key Patents and Exclusivity Periods

The core patent protecting JAKAFI is U.S. Patent No. 7,598,257, titled "Janus Kinase Inhibitors." This patent claims ruxolitinib and its use in treating myeloproliferative disorders. The initial term of this patent expired in August 2024. However, patent term extensions (PTEs) and other patent filings can significantly alter the effective market exclusivity period.

The U.S. Food and Drug Administration (FDA) granted a PTE for JAKAFI, extending market exclusivity. The exact duration of the PTE is calculated based on the regulatory review period and is subject to specific criteria. Information on the granted PTE for JAKAFI indicates an extension of its market exclusivity. [1]

Beyond the core patent, Incyte has pursued and obtained additional patents covering various aspects of JAKAFI, including:

• Formulations: Patents related to specific salt forms, crystalline structures, or delivery methods of ruxolitinib.
• Manufacturing Processes: Patents protecting novel or improved methods for synthesizing ruxolitinib.
• New Indications: Patents claiming the use of ruxolitinib for treating diseases other than those for which it was initially approved. For example, JAKAFI is approved for GvHD, and patent protection for this indication is crucial.

The landscape of patent litigation for JAKAFI involves challenges from generic manufacturers seeking to enter the market. These challenges often target the validity or enforceability of Incyte's patents. Successful invalidation of key patents can lead to earlier generic competition and a decline in JAKAFI's revenue. [2]

Regulatory Approvals and Market Authorization

JAKAFI received its first U.S. FDA approval in November 2011 for the treatment of intermediate or high-risk myelofibrosis. Subsequent approvals expanded its use:

• Polycythemia Vera (PV): Approved in December 2014 for patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.
• Graft-versus-Host Disease (GvHD): Approved in February 2017 for patients aged 12 years and older with acute GvHD after failure of one or two systemic therapies and in February 2022 for chronic GvHD after failure of at least two prior lines of systemic therapy. [3]

In Europe, JAKAFI (marketed as Jakavi) received its first Marketing Authorisation from the European Medicines Agency (EMA) in August 2012 for myelofibrosis. Subsequent approvals have followed for PV and GvHD, mirroring U.S. indications. [4]

The breadth of these approvals across multiple serious conditions underpins JAKAFI's significant market potential and revenue generation. Each indication has a distinct patient population and treatment pathway, contributing to the drug's overall commercial success.

JAKAFI Financial Performance and Market Trajectory

Incyte Corporation's financial reports detail the commercial performance of JAKAFI. The drug has consistently been a primary revenue driver for the company.

Revenue Generation and Growth Trends

JAKAFI has demonstrated strong revenue growth since its launch.

Year	Global Net Product Sales (USD billions)
2020	2.03
2021	2.26
2022	2.45
2023	2.71

Source: Incyte Corporation Annual Reports [5, 6, 7, 8]

The consistent year-over-year growth reflects increasing patient access, expanded indications, and market penetration in its approved therapeutic areas. The drug's performance is closely monitored by investors and industry analysts.

Factors Influencing Future Revenue

Several factors will shape JAKAFI's future financial trajectory:

• Patent Expiration and Generic Competition: The expiration of key patents, particularly U.S. Patent No. 7,598,257, opens the door for generic manufacturers. The timing of generic market entry depends on the outcome of patent litigation and potential circumvention strategies employed by competitors. A significant influx of generic competitors post-patent expiration could lead to substantial price erosion and a decline in JAKAFI's sales. [2]
• Lifecycle Management and New Indications: Incyte's strategy to extend JAKAFI's lifecycle involves seeking approval for new indications. Success in these endeavors can significantly prolong the drug's revenue-generating period. Conversely, failure to gain approval for new uses or a lack of robust clinical data for expanded indications will limit future growth.
• Market Penetration in Existing Indications: Continued efforts to increase physician and patient awareness, coupled with market access initiatives, can further drive penetration within the MF, PV, and GvHD patient populations.
• Competitive Landscape: The emergence of new therapeutic agents for MF, PV, and GvHD can create competitive pressure. Novel therapies with improved efficacy, safety profiles, or administration convenience could draw patients away from JAKAFI. For example, competition in the myelofibrosis space has intensified with the introduction of other JAK inhibitors and novel agents. [9]
• Pricing and Reimbursement: Changes in healthcare policies, payer reimbursement decisions, and drug pricing regulations can impact JAKAFI's market access and affordability, thereby affecting sales volumes and revenue.

Geographic Market Performance

JAKAFI generates significant revenue across multiple global markets. North America and Europe are typically the largest contributors, followed by other regions.

Region	2023 Net Product Sales (USD millions)
United States	1,420
Europe	795
Rest of World	496

Source: Incyte Corporation 2023 Annual Report [8]

The performance in emerging markets is a key area for future growth, contingent on regulatory approvals and market access initiatives.

JAKAFI R&D Pipeline and Strategic Considerations

Incyte's ongoing research and development efforts are critical to maintaining and expanding JAKAFI's market position and its pipeline's overall value.

Development of New Indications

Incyte continues to investigate JAKAFI in clinical trials for new therapeutic areas. These efforts are crucial for identifying new revenue streams and extending the drug's commercial life post-patent expiry. Specific areas of ongoing research include, but are not limited to, autoimmune diseases and other inflammatory conditions. [10]

Combination Therapies

Exploring the use of JAKAFI in combination with other agents is a common strategy to enhance efficacy or overcome resistance mechanisms. Clinical trials assessing such combinations are vital for understanding JAKAFI's potential in broader therapeutic strategies. Data from these trials will inform future market positioning and potential label expansions.

Oral JAK Inhibitor Landscape

JAKAFI is an oral medication, offering a significant advantage in patient convenience. However, the market is increasingly seeing the development of other oral JAK inhibitors, as well as novel oral agents targeting different pathways. The efficacy, safety, and tolerability profiles of these competing therapies will be critical determinants of JAKAFI's long-term competitive standing.

Key Takeaways

• Patent Expiration Risk: The expiration of JAKAFI's foundational patents presents a significant risk of generic competition, which could lead to substantial revenue erosion. Patent litigation outcomes will be a critical determinant of market exclusivity duration.
• Diversified Indications Drive Revenue: JAKAFI's multiple FDA and EMA approvals for myelofibrosis, polycythemia vera, and graft-versus-host disease have established it as a consistent revenue generator for Incyte.
• Ongoing R&D is Crucial: Incyte's continued investment in exploring new indications and combination therapies for JAKAFI is essential for lifecycle management and mitigating the impact of patent expiry.
• Competitive Market: The market for JAK inhibitors and treatments for myeloproliferative neoplasms and GvHD is dynamic, with new entrants and therapeutic advancements posing ongoing competitive challenges.

Frequently Asked Questions

1. When did the primary patent for JAKAFI expire in the United States? The primary patent protecting JAKAFI, U.S. Patent No. 7,598,257, expired in August 2024.

2. What are the main therapeutic areas for which JAKAFI is approved? JAKAFI is approved for myelofibrosis, polycythemia vera, and graft-versus-host disease.

3. How significant has JAKAFI been to Incyte's revenue? JAKAFI has been Incyte's primary revenue driver, generating over \$2.7 billion in global net product sales in 2023.

4. What is the primary risk associated with JAKAFI's future market performance? The primary risk is the anticipated entry of generic competition following the expiration of its key patents.

5. Is Incyte developing JAKAFI for any new indications? Yes, Incyte is actively investigating JAKAFI in clinical trials for new indications, including various autoimmune and inflammatory diseases.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/therapeutic-equivalence-ratings-are-ratings-drug-products/orange-book-approved-drug-products-therapeutic-equivalence-evaluations

[2] U.S. Patent and Trademark Office. (n.d.). Patent Litigation Search. Retrieved from USPTO website (specific search requires access to litigation databases).

[3] U.S. Food and Drug Administration. (n.d.). Drug Search and Database. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases

[4] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from EMA website.

[5] Incyte Corporation. (2021). 2020 Annual Report.

[6] Incyte Corporation. (2022). 2021 Annual Report.

[7] Incyte Corporation. (2023). 2022 Annual Report.

[8] Incyte Corporation. (2024). 2023 Annual Report.

[9] Veran, P., et al. (2019). Ruxolitinib in primary or post-polycythemia vera myelofibrosis. New England Journal of Medicine, 371(14), 1310-1319.

[10] Incyte Corporation. (n.d.). Clinical Trials and Research. Retrieved from Incyte Corporation website.